tiprankstipranks
Urogen Pharma (URGN)
NASDAQ:URGN
US Market
URGN
Urogen Pharma
RESEARCH TOOLSreports
Want to see URGN full AI Analyst Report?

Urogen Pharma (URGN) Stock Forecast & Price Target

663 Followers
See the Price Targets and Ratings of:

URGN Analyst Ratings

Strong Buy
6Ratings
Strong Buy
5 Buy
1 Hold
0 Sell
Based on 6 analysts giving stock ratings to
Urogen
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

URGN Stock 12 Month Forecast

Average Price Target

$45.67
▲(11.46% Upside)
Based on 6 Wall Street analysts offering 12 month price targets for Urogen Pharma in the last 3 months. The average price target is $45.67 with a high forecast of $50.00 and a low forecast of $42.00. The average price target represents a 11.46% change from the last price of $40.97.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","51":"$51","21.75":"$21.8","31.5":"$31.5","41.25":"$41.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.666666666666664,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$45.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$42.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,21.75,31.5,41.25,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.94,38.86769230769231,39.79538461538461,40.723076923076924,41.65076923076923,42.57846153846154,43.50615384615384,44.433846153846154,45.36153846153846,46.28923076923077,47.216923076923074,48.144615384615385,49.07230769230769,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.94,38.53435897435897,39.12871794871795,39.723076923076924,40.31743589743589,40.91179487179487,41.50615384615384,42.10051282051282,42.694871794871794,43.28923076923077,43.88358974358974,44.47794871794871,45.07230769230769,{"y":45.666666666666664,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.94,38.25230769230769,38.56461538461538,38.87692307692308,39.18923076923077,39.50153846153846,39.81384615384615,40.12615384615385,40.43846153846154,40.75076923076923,41.06307692307692,41.37538461538462,41.68769230769231,{"y":42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.02,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.815,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.47,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.42,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.7,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.02,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.03,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$45.67Lowest Price Target$42.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on URGN
Michael Schmidt
Guggenheim
Guggenheim
$32→$42
Buy
2.51%
Upside
Assigned
07/21/26
UroGen Pharma price target raised to $42 from $32 at GuggenheimUroGen Pharma price target raised to $42 from $32 at Guggenheim
TD Cowen Analyst forecast on URGN
Tara Bancroft
TD Cowen
TD Cowen
$35→$50
Buy
22.04%
Upside
Reiterated
07/20/26
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy Rating
H.C. Wainwright Analyst forecast on URGN
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$45
Buy
9.84%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (NASDAQ: RANI), Urogen Pharma (NASDAQ: URGN) and vTv Therapeutics (NASDAQ: VTVT)
Oppenheimer Analyst forecast on URGN
Leland Gershell
Oppenheimer
Oppenheimer
$40→$50
Buy
22.04%
Upside
Assigned
07/16/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Urogen Pharma (NASDAQ: URGN)
Goldman Sachs Analyst forecast on URGN
Paul Choi
Goldman Sachs
Goldman Sachs
$18→$44
Hold
7.40%
Upside
Reiterated
07/15/26
UroGen Pharma price target raised to $44 from $18 at Goldman SachsUroGen Pharma price target raised to $44 from $18 at Goldman Sachs
Ladenburg Thalmann & Co. Analyst forecast on URGN
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$43
Buy
4.95%
Upside
Initiated
05/11/26
UroGen Pharma assumed with a Buy at LadenburgUroGen Pharma assumed with a Buy at Ladenburg
Piper Sandler Analyst forecast on URGN
Kelsey Goodwin
Piper Sandler
Piper Sandler
$40
Buy
-2.37%
Downside
Reiterated
04/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on URGN
Amin Makarem
Jefferies
Jefferies
$40
Buy
-2.37%
Downside
Initiated
04/09/26
UroGen Pharma initiated with a Buy at JefferiesUroGen Pharma initiated with a Buy at Jefferies
Scotiabank Analyst forecast on URGN
George Farmer
Scotiabank
Scotiabank
$47
Buy
14.72%
Upside
Reiterated
08/06/25
Scotiabank Reaffirms Their Buy Rating on Urogen Pharma (URGN)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on URGN
Michael Schmidt
Guggenheim
Guggenheim
$32→$42
Buy
2.51%
Upside
Assigned
07/21/26
UroGen Pharma price target raised to $42 from $32 at GuggenheimUroGen Pharma price target raised to $42 from $32 at Guggenheim
TD Cowen Analyst forecast on URGN
Tara Bancroft
TD Cowen
TD Cowen
$35→$50
Buy
22.04%
Upside
Reiterated
07/20/26
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy Rating
H.C. Wainwright Analyst forecast on URGN
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$45
Buy
9.84%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (NASDAQ: RANI), Urogen Pharma (NASDAQ: URGN) and vTv Therapeutics (NASDAQ: VTVT)
Oppenheimer Analyst forecast on URGN
Leland Gershell
Oppenheimer
Oppenheimer
$40→$50
Buy
22.04%
Upside
Assigned
07/16/26
Analysts Offer Insights on Healthcare Companies: Legend Biotech (NASDAQ: LEGN) and Urogen Pharma (NASDAQ: URGN)
Goldman Sachs Analyst forecast on URGN
Paul Choi
Goldman Sachs
Goldman Sachs
$18→$44
Hold
7.40%
Upside
Reiterated
07/15/26
UroGen Pharma price target raised to $44 from $18 at Goldman SachsUroGen Pharma price target raised to $44 from $18 at Goldman Sachs
Ladenburg Thalmann & Co. Analyst forecast on URGN
Kevin DeGeeter
Ladenburg Thalmann & Co.
Ladenburg Thalmann & Co.
$43
Buy
4.95%
Upside
Initiated
05/11/26
UroGen Pharma assumed with a Buy at LadenburgUroGen Pharma assumed with a Buy at Ladenburg
Piper Sandler Analyst forecast on URGN
Kelsey Goodwin
Piper Sandler
Piper Sandler
$40
Buy
-2.37%
Downside
Reiterated
04/20/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on URGN
Amin Makarem
Jefferies
Jefferies
$40
Buy
-2.37%
Downside
Initiated
04/09/26
UroGen Pharma initiated with a Buy at JefferiesUroGen Pharma initiated with a Buy at Jefferies
Scotiabank Analyst forecast on URGN
George Farmer
Scotiabank
Scotiabank
$47
Buy
14.72%
Upside
Reiterated
08/06/25
Scotiabank Reaffirms Their Buy Rating on Urogen Pharma (URGN)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Urogen Pharma

3 Months
Ram SelvarajuH.C. Wainwright
Success Rate
10/15 ratings generated profit
67%
Average Return
+3.41%
Copying Ram Selvaraju's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.41% per trade.
1 Year
Tara BancroftTD Cowen
Success Rate
13/17 ratings generated profit
76%
Average Return
+59.25%
Copying Tara Bancroft's trades and holding each position for 1 Year would result in 76.47% of your transactions generating a profit, with an average return of +59.25% per trade.
2 Years
Tara BancroftTD Cowen
Success Rate
16/17 ratings generated profit
94%
Average Return
+130.67%
Copying Tara Bancroft's trades and holding each position for 2 Years would result in 94.12% of your transactions generating a profit, with an average return of +130.67% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

URGN Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
5
8
9
7
4
Buy
0
0
6
8
13
Hold
0
0
1
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
8
16
16
19
In the current month, URGN has received 17 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. URGN average Analyst price target in the past 3 months is 45.67.
Each month's total comprises the sum of three months' worth of ratings.

URGN Financial Forecast

URGN Earnings Forecast

Next quarter’s earnings estimate for URGN is -$0.27 with a range of -$0.61 to -$0.16. The previous quarter’s EPS was -$0.47. URGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year URGN has Performed in-line its overall industry.
Next quarter’s earnings estimate for URGN is -$0.27 with a range of -$0.61 to -$0.16. The previous quarter’s EPS was -$0.47. URGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year URGN has Performed in-line its overall industry.

URGN Sales Forecast

Next quarter’s sales forecast for URGN is $63.55M with a range of $56.91M to $67.50M. The previous quarter’s sales results were $50.96M. URGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year URGN has Performed in-line its overall industry.
Next quarter’s sales forecast for URGN is $63.55M with a range of $56.91M to $67.50M. The previous quarter’s sales results were $50.96M. URGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year URGN has Performed in-line its overall industry.

URGN Stock Forecast FAQ

What is URGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Urogen Pharma’s 12-month average price target is 45.67.
    What is URGN’s upside potential, based on the analysts’ average price target?
    Urogen Pharma has 11.46% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is URGN a Buy, Sell or Hold?
          Urogen Pharma has a consensus rating of Strong Buy which is based on 5 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Urogen Pharma’s price target?
            The average price target for Urogen Pharma is 45.67. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $42.00. The average price target represents 11.46% Increase from the current price of $40.97.
              What do analysts say about Urogen Pharma?
              Urogen Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
                How can I buy shares of URGN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.